* Genetics Institute Inc., of Cambridge, Mass., began U.S. clinicaltrials of recombinant human Factor IX for treatment of hemophilia B,which is a blood coagulation disease caused by a deficiency of FactorIX.

* PerSeptive Biosystems Inc., of Cambridge, Mass., adopted ashareholder rights plan as a protection against hostile takeovers. Thecompany said the move was not a response to any specific acquisitioneffort.

* Corvas International Inc., of San Diego, settled a shareholderslawsuit involving allegations the company failed to discloseinformation related to a strategic alliance with Centocor Inc., ofMalvern, Pa. Corvas denied all claims of wrongdoing. It agreed topay $200,000 in cash and 125,000 newly issued shares to settle thecase. Corvas said its insurer and Centocor, also named as adefendant, will contribute additional amounts, which were notdisclosed. Corvas said it will take a $535,000 charge to earnings inthe quarter ending Dec. 31, 1994 for the settlement.

(c) 1997 American Health Consultants. All rights reserved.